Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SYDNEY, Australia, Aug. 15, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) is pleased to announce that it has received a €876,635 (A$1,306,266) cash rebate from the French Government under its Crédit d’Impôt Recherche scheme (CIR). Through CIR the French government reimburses companies, whether French or international, for undertaking research and development activity in France by up to 30%.
Prima BioMed qualifies to receive CIR credits via its subsidiary Immutep due to R&D conducted in its laboratory at Châtenay-Malabry in southwestern Paris in the 2016 calendar year. Prima is currently working on new products in addition to the development work related to lead compound IMP321, in both cancer treatment and other settings.
The additional funding will be used for the development of its IMP321 clinical trial programs in Europe and Australia.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
